The spine journal : official journal of the North American Spine Society · 2025
Semaglutide use is associated with higher rates of pseudarthrosis and dysphagia in patients undergoing posterior cervical fusion.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ng Mitchell K, Mastrokostas Paul G, Mastrokostas Leonidas E, Tabbaa Ameer, Johnson Matthew, Monsef Jad Bou, Razi Afshin E
Аннотация
BACKGROUND CONTEXT: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown efficacy in managing glycemic control and obesity but its effects on surgical outcomes, particularly in posterior cervical fusion (PCF), are underexplored.
PURPOSE: To evaluate the association between semaglutide use and postoperative complications, costs, and readmissions in patients undergoing PCF.
DESIGN: Retrospective cohort study.
PATIENT SAMPLE: Patients undergoing PCF were queried from the PearlDiver Mariner database between 2010 and 2022.
OUTCOME MEASURES: Outcomes included medical and surgical complications, readmissions, emergency department visits, and associated costs within 90 days and 2 years postoperatively.
METHODS: Patients with an active semaglutide prescription were propensity score-matched in a 1:5 ratio to controls based on age, sex, Elixhauser Comorbidity Index, and other clinical variables. Statistical analyses included chi-square tests and logistic regression, with significance set at p<.003 after Bonferroni correction.
RESULTS: A total of 340 semaglutide users and 1,540 matched controls were included. Semaglutide use was associated with significantly higher odds of pseudoarthrosis at 2 years (OR 4.79, 95% CI 3.11-7.37; p<.001) and dysphagia (OR 2.12, 95% CI 1.46-3.03; p<.001). Hospital cost analyses revealed significant differences between groups. Same-day ($5,000 vs $11,700; p<.001) and mean 90-day costs were significantly lower ($12,200 vs $18,800; p<.001) in the semaglutide group. No differences were observed in emergency department visits or readmissions (p>.003 for all).
CONCLUSIONS: Semaglutide use is associated with an increased risk of long-term complications, including pseudoarthrosis and dysphagia, as well as lower same-day and 90-day costs in patients undergoing PCF. These findings highlight the importance of careful perioperative management of semaglutide users to optimize outcomes while leveraging its purported benefits.
PURPOSE: To evaluate the association between semaglutide use and postoperative complications, costs, and readmissions in patients undergoing PCF.
DESIGN: Retrospective cohort study.
PATIENT SAMPLE: Patients undergoing PCF were queried from the PearlDiver Mariner database between 2010 and 2022.
OUTCOME MEASURES: Outcomes included medical and surgical complications, readmissions, emergency department visits, and associated costs within 90 days and 2 years postoperatively.
METHODS: Patients with an active semaglutide prescription were propensity score-matched in a 1:5 ratio to controls based on age, sex, Elixhauser Comorbidity Index, and other clinical variables. Statistical analyses included chi-square tests and logistic regression, with significance set at p<.003 after Bonferroni correction.
RESULTS: A total of 340 semaglutide users and 1,540 matched controls were included. Semaglutide use was associated with significantly higher odds of pseudoarthrosis at 2 years (OR 4.79, 95% CI 3.11-7.37; p<.001) and dysphagia (OR 2.12, 95% CI 1.46-3.03; p<.001). Hospital cost analyses revealed significant differences between groups. Same-day ($5,000 vs $11,700; p<.001) and mean 90-day costs were significantly lower ($12,200 vs $18,800; p<.001) in the semaglutide group. No differences were observed in emergency department visits or readmissions (p>.003 for all).
CONCLUSIONS: Semaglutide use is associated with an increased risk of long-term complications, including pseudoarthrosis and dysphagia, as well as lower same-day and 90-day costs in patients undergoing PCF. These findings highlight the importance of careful perioperative management of semaglutide users to optimize outcomes while leveraging its purported benefits.